drugset / Trial / NCT00277914

Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

NCT00277914 ↗

Phase 3 Completed 749 enrolled Sprout Pharmaceuticals, Inc
NaSingle-groupOpen-labelTreatment

Summary

To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.

Timeline

Start
2006-01
Primary completion
2007-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject flibanserin Small molecule — —

Indications